About MIFCOR

About company

MIFCOR is addressing this great need by developing a first-in-class biologic therapeutic for protecting tissue from cell death following reduced blood flow (ischemia). Their therapeutic, MIF-2, takes advantage of breakthrough science: by targeting a novel biological pathway, it protects tissue from ischemia-induced death. They successfully executed an exclusive option on an IP portfolio and building a business plan.